Navigant Consulting, Inc. (NCI) Analysts See $0.11 EPS; Kura Oncology (KURA) Sellers Decreased By 3.58% Their Shorts

Kura Oncology, Inc. (NASDAQ:KURA) Logo

Kura Oncology Inc (NASDAQ:KURA) had a decrease of 3.58% in short interest. KURA’s SI was 2.79 million shares in April as released by FINRA. Its down 3.58% from 2.90M shares previously. With 224,400 avg volume, 13 days are for Kura Oncology Inc (NASDAQ:KURA)’s short sellers to cover KURA’s short positions. The stock decreased 2.99% or $0.47 during the last trading session, reaching $15.26. About 117,343 shares traded. Kura Oncology, Inc. (NASDAQ:KURA) has declined 32.98% since April 13, 2018 and is downtrending. It has underperformed by 37.35% the S&P500. Some Historical KURA News: 22/05/2018 – OncoDNA announces screening collaboration with Kura Oncology; 09/04/2018 – Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018; 08/04/2018 – NIGERIAN ARMY: 149 HOSTAGES RESCUED IN YERIMERI KURA VILLAGE; 12/03/2018 – KURA ONCOLOGY INC – SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR KO-539 IN LATE 2018 OR EARLY 2019; 16/05/2018 – Kura Oncology at Non-Deal Roadshow Hosted By Wedbush Today; 08/05/2018 – Kura Oncology 1Q Loss/Shr 46c; 22/05/2018 – ONCODNA SAYS FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED; 08/05/2018 – KURA ONCOLOGY – EXPECTS CURRENT CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS TO BE SUFFICIENT TO FUND CURRENT OPERATIONS INTO FIRST HALF OF 2020; 12/03/2018 – KURA ONCOLOGY INC – QTRLY SHR LOSS $0.37; 12/03/2018 – KURA ONCOLOGY INC – PLANS TO INITIATE TIPIFARNIB AIM-HN TRIAL IN HRAS MUTANT HNSCC IN SECOND HALF OF 2018

Analysts expect Navigant Consulting, Inc. (NYSE:NCI) to report $0.11 EPS on May, 1.They anticipate $0.19 EPS change or 63.33% from last quarter’s $0.3 EPS. NCI’s profit would be $4.46 million giving it 46.36 P/E if the $0.11 EPS is correct. After having $0.10 EPS previously, Navigant Consulting, Inc.’s analysts see 10.00% EPS growth. The stock decreased 0.05% or $0.01 during the last trading session, reaching $20.4. About 380,493 shares traded. Navigant Consulting, Inc. (NYSE:NCI) has risen 2.09% since April 13, 2018 and is uptrending. It has underperformed by 2.28% the S&P500. Some Historical NCI News: 08/05/2018 – Navigant Research Report Shows Revenue for Sales and Installation of Electric Vehicle Supply Equipment Is Expected to Reach Nearly $36 Billion in 2027; 22/05/2018 – Navigant Research Report Shows a New Generation of Projects Combining Energy Storage with Fossil Fuel Generators Is Shifting the Traditional Paradigm; 08/05/2018 – lntegreon Names Jamie Berry Managing Director of Litigation Services; 02/05/2018 – Navigant Research Report Finds the Global Market for Off-Grid DER Implementation Is Expected to Total Approximately $350 Billio; 10/05/2018 – Navigant: Entered Into an Agreement With Engine Cap, End Its Current Proxy Contest; 21/05/2018 – Navigant Consulting Rises for 12 Days: Longest Streak Since IPO; 29/05/2018 – Navigant Research Names Tendril a Leader in the Home Energy Management Market; 29/03/2018 – Navigant Research Report Shows New Global Capacity Deployments for Energy Storage for the Grid and Ancillary Services Are Expected to Exceed 29 GW by 2027; 03/04/2018 – NAVIGANT HOLDER ENGINE CAPITAL CONCERNED CO. MAY DELAY AGM; 22/03/2018 – As Healthcare Becomes a Value Proposition for the Smart Home, Navigant Research Expects a Range of Opportunities for Stakeholders

Among 3 analysts covering Navigant Consulting (NYSE:NCI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Navigant Consulting had 4 analyst reports since February 25, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 27 by Sidoti. On Monday, February 25 the stock rating was maintained by Barrington with “Buy”. SunTrust maintained the stock with “Hold” rating in Wednesday, February 27 report.

Investors sentiment decreased to 0.89 in 2018 Q4. Its down 0.12, from 1.01 in 2018Q3. It worsened, as 20 investors sold Navigant Consulting, Inc. shares while 61 reduced holdings. 29 funds opened positions while 43 raised stakes. 38.01 million shares or 3.86% less from 39.53 million shares in 2018Q3 were reported. James Inv Rech Inc invested in 46,770 shares or 0.07% of the stock. Symphony Asset Mngmt has invested 0.07% in Navigant Consulting, Inc. (NYSE:NCI). Northwest Inv Counselors Limited has 44,586 shares for 0.47% of their portfolio. 65,673 were reported by Credit Suisse Ag. Pzena Mngmt Ltd Liability reported 1.14 million shares. Cwm Lc stated it has 0% of its portfolio in Navigant Consulting, Inc. (NYSE:NCI). California Employees Retirement Systems owns 137,019 shares. New York-based Ny State Common Retirement Fund has invested 0% in Navigant Consulting, Inc. (NYSE:NCI). Tci Wealth Advsrs Incorporated reported 76 shares stake. Element Mgmt Limited Liability Company reported 0.01% in Navigant Consulting, Inc. (NYSE:NCI). 8,853 are held by Riverhead Mgmt Ltd Limited Liability Company. Texas Permanent School Fund stated it has 0.01% in Navigant Consulting, Inc. (NYSE:NCI). Magnetar Ltd Limited Liability Company accumulated 0.01% or 10,003 shares. Amer Interest Group has invested 0% of its portfolio in Navigant Consulting, Inc. (NYSE:NCI). Stone Ridge Asset Mngmt Limited Liability has 42,855 shares for 0.06% of their portfolio.

Navigant Consulting, Inc. provides professional services to corporate executives and senior management, corporate counsel, law firms, corporate boards, special committees, and governmental agencies worldwide. The company has market cap of $826.60 million. The firm operates through four divisions: Healthcare; Energy; Financial Services Advisory and Compliance; and Disputes, Forensics & Legal Technology. It has a 7.74 P/E ratio. The Healthcare segment provides consulting and business process management services to healthcare providers, payers, and life sciences companies.

More notable recent Navigant Consulting, Inc. (NYSE:NCI) news were published by: which released: “NCI Building Systems and Ply Gem Building Products Create Cornerstone Building Brands Following Merger – PRNewswire” on April 11, 2019, also with their article: “Hemispherx Reports 2018 Year-end Financial Results NYSE:HEB – GlobeNewswire” published on April 01, 2019, published: “Navigant (NYSE:NCI) Downgraded By William Blair On Lack Of 2019 Visibility – Benzinga” on August 03, 2018. More interesting news about Navigant Consulting, Inc. (NYSE:NCI) were released by: and their article: “Why Navigant Consulting Stock Got Crushed Today – Nasdaq” published on February 26, 2019 as well as‘s news article titled: “West Named as a Philadelphia Business Journal 2019 Faces of Philanthropy Honoree – PRNewswire” with publication date: April 12, 2019.

More notable recent Kura Oncology, Inc. (NASDAQ:KURA) news were published by: which released: “Kura up 1% on tipifarnib data – Seeking Alpha” on April 03, 2019, also with their article: “Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications – GlobeNewswire” published on April 02, 2019, published: “Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon — What Drives Growth in Today’s Competitive Landscape – GlobeNewswire” on March 29, 2019. More interesting news about Kura Oncology, Inc. (NASDAQ:KURA) were released by: and their article: “Kura Oncology to Participate in Two Upcoming Investor Conferences – Nasdaq” published on March 06, 2019 as well as‘s news article titled: “The Prognosis For Kura Oncology – Seeking Alpha” with publication date: February 18, 2019.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. The company has market cap of $582.46 million. The Company’s pipeline consists of small molecule product candidates that target cancer. It currently has negative earnings. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia.

Navigant Consulting, Inc. (NYSE:NCI) Institutional Positions Chart